Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Lindy Visser

Postdoc
  • Single Cell Genomics
Map the immune microenvironment of pediatric solid tumors
Phone 088 97 27 686

Immunotherapies have shown to be a great promise in treating pediatric cancers, although clinical successes in solid tumors have been limited. Among other things this is because current studies are hampered by the lack of knowledge on the composition and function of the pediatric cancer immune microenvironment. As an expert in single-cell readouts, with a wet-lab and dry-lab background in molecular pathology and tumor immunology, that is where I come in. Next to my day-to-day facility-work, I’m heavily involved in projects aiming to map the immune microenvironment of pediatric solid tumors. My ultimate goal is to foster the development of (novel) immunotherapeutic strategies to treat pediatric cancers. To achieve this, I’m collaborating with several research groups from the Princess Maxima Center and UMCU.

  • Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

    • feb. 2024
    • Judith, Wienke, et al
    • Cancer Cell
  • Ewing Sarcoma Single-cell Transcriptome Analysis Reveals Functionally Impaired Antigen-presenting Cells

    • jan. 2023
    • Lindy L., Visser, et al
    • Cancer Research Communications
  • Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma

    • jan. 2023
    • Jeff, DeMartino, et al
    • Nature communications
  • Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk

    • okt. 2022
    • , et al
    • British Journal of Cancer
  • 06.03 Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

    • sep. 2022
    • J, Wienke, et al
View all publications